Abstract
Objectives
Quantitative glycemic metrics are needed to identify undiagnosed celiac disease in type 1 diabetes and reduce delays in celiac diagnosis. Celiac enteropathy drives malabsorption that increases the risk of prandial insulin-glucose mismatch and hypoglycemia. We assessed if children with type 1 diabetes and celiac disease have lower post-prandial glucose levels preceding celiac diagnosis vs. those without celiac disease, leveraging continuous glucose monitoring (CGM) data and a computational meal annotation algorithm.
Methods
In this retrospective cohort study, children with type 1 diabetes <12 months duration using CGM, positive celiac serologies and biopsy confirmed celiac disease (n=16) were matched 1-to-4 to those with negative celiac serologies (n=60). Meals were computationally annotated in the 30-day window before serologies. Differences in post-prandial trough glucose and other prandial glycemic outcomes were assessed via mixed models.
Results
Undiagnosed celiac disease was associated with a lower glucose rise from meal start to peak vs. no celiac disease (−8.9 %, 95 % CI, −14.9–−2.5 %, p=0.009) and, during the first meal of the day, a lower fall from peak to trough (−9.3 %, 95 % CI, −16.5 %–−1.5 %, p=0.02). There was no significant association between celiac disease and trough glucose, meal hypoglycemia or time hypoglycemic.
Conclusions
Computational analysis revealed that blunted prandial glycemic trajectories, not hypoglycemia, are associated with undiagnosed celiac disease in children with type 1 diabetes using CGM. These findings challenge current guidelines, and future studies should validate and integrate these glycemic biomarkers into a CGM-based model for real-time prediction of celiac disease in type 1 diabetes.
Introduction
Timely diagnosis of celiac disease (CD) among children with type 1 diabetes mellitus (T1D) is imperative to mitigate complications, yet diagnosis remains challenging. Patients with T1D have a higher prevalence of CD [1], [2], [3], [4], [5] (1–16.4 % [4] in T1D vs. 0.2–5.5 % [6] overall) but people with T1D are more often asymptomatic [1], [7], [8], [9] and classic CD symptoms are unreliable predictors of the disease in this population [10]. Treatment of CD is crucial to prevent lower bone mineral density [11], poor growth and gastrointestinal malignancy [4], as well as complications with the dual CD and T1D diagnosis, including an increased risk of dyslipidemia [12], 13] and microvascular disease [14], 15].
Enteropathy secondary to CD impairs intestinal digestion and nutrient absorption [16]. In people with T1D, carbohydrate malabsorption increases the risk of mismatch between prandial insulin and serum glucose, which can alter post-prandial glucose patterns including an increased risk of hypoglycemia. While increased or unexplained hypoglycemia is a guideline-based indication to screen for CD in patients with T1D [4], 5], clinicians lack guidance on quantitative metrics of hypoglycemia or other continuous glucose monitor (CGM) data features that might indicate CD. Past pediatric T1D studies, predating common CGM use, demonstrated higher rates of hypoglycemia [17], 18] and/or lower hemoglobin A1c (HbA1c) [19] at CD diagnosis, though subsequent studies have not replicated these findings [8], 20], 21].
CGM measure high-resolution glucose data, providing novel, granular insights into glucose dynamics, namely, the magnitude and pace of glucose rise and fall. Computational analyses of CGM prandial glucose dynamics are an emerging tool to distinguish glycemic features of underlying pathology [22], and may identify a signature of insulin-glucose mismatch and dysglycemia associated with CD to help guide clinical care. Toward this end, we tested the hypothesis that exposure to malabsorption from CD in T1D increases post-prandial hypoglycemia and alters prandial glycemia in a retrospective cohort of children with new-onset T1D using CGM prior to CD diagnosis.
Materials and methods
Study cohort
We performed a retrospective analysis of a matched cohort drawn from a study cohort of children aged 2–21 years followed in the Boston Children’s Hospital (BCH) T1D program. This study was conducted in accordance with the Declaration of Helsinki. This study protocol was reviewed and received Ethical Approval from the Boston Children’s Hospital Institutional Review Board, approval number IRB-P00032591 on July 12, 2019. The need for written informed consent was waived for this retrospective study by the Institutional Review Board.
The study cohort included individuals diagnosed with T1D from January 1, 2015 (beginning of BCH CGM database) to December 30, 2022. Eligible subjects did not have a diagnosis of CD at the time of diabetes diagnosis, underwent celiac serologies <12 months following diabetes diagnosis, used Dexcom CGM (DexCom, Inc., San Diego, CA, USA) in the month prior to serologies and shared CGM data with BCH via the cloud-based Dexcom Clarity Portal. We excluded children using automated insulin delivery technology including predictive low glucose suspend features and/or with gastrointestinal comorbidities (e.g. inflammatory bowel disease).
Exposure definition
The exposure of interest was undiagnosed CD. The exposure window was the 30 days prior to a documented celiac antibody testing date (i.e., index date) (Figure 1A). The index date for one individual was the date of follow-up serologies after initial positive serologies, as they started CGM in the interim but were advised to continue consuming gluten with documented gluten intake between serologies. Confirmed CD (CD+) was defined using the gold standard, i.e., duodenal histologic findings of crypt hyperplasia, villous atrophy and intraepithelial lymphocytosis plus elevated tissue transglutaminase IgA [23]. Those unexposed to CD (CD−) were defined as those with normal CD serologies.

Study design and prandial outcome definitions. (A) Schematic of cohort characteristics and timing of celiac screening test (measurement of exposure) relative to the window for CGM outcome analysis in the matched cohort. (B) Schematic depicting definitions of prandial glucose outcomes. Meals were inferred by first identifying a glucose peak with a subsequent glucose trough. The meal glucose start was defined as an inflection from downtrending to uptrending glucose preceding the peak. Meal glucose rise (rise) was calculated as peak minus start and rise velocity was calculated as rise divided by time from start to peak. Meal glucose fall (fall) was calculated as the absolute value of trough minus peak and fall velocity was calculated as fall divided by time from peak to trough. CD−, no celiac disease; CD+, undiagnosed celiac disease; CGM, continuous glucose monitoring; AUC, area under curve. Created in BioRender. Ruiz, J. (2025) https://BioRender.com/2x4rz0m.
Matched cohort criteria
Demographic and clinical data were collected via retrospective chart review. Potential subjects were only eligible for matching if their CGM data met sufficiency criteria. CD+ children were randomly matched with up to four CD−, using five clinical covariates to adjust for confounding from clinically-relevant physiologic states. Covariates were dichotomized to perform exact matching: sex, pubertal age (males ≥11.5 years [median age to attain testicular volume ≥4 mL [24]]; females ≥10 years [median age to observe Tanner stage II breast development in girls with BMI 10–84th percentile [25]]), longer diabetes duration (≥6 months), overweight (BMI z-score ≥1.0, corresponding to the overweight definition ≥85th percentile [5]) and above target hemoglobin HbA1c ≥7.5 % (accepted target for children who do not utilize automated insulin delivery [5]). Subjects with identical combinations of matching covariates were combined into the same strata for more statistically efficient analyses. Combined race and ethnicity categories were recorded but not used for matching. Individuals with Hispanic race or ethnicity recorded were categorized as Hispanic and all other race/ethnicity categories represent non-Hispanic individuals.
Prandial and summative glucose outcomes
Our prandial outcomes quantify prandial dynamics, identified as periods of transient glucose rise, peak (maximal excursion), fall and trough (post-prandial nadir) most likely to represent meals. The primary outcome was meal trough glucose, selected to operationalize the evaluation of post-prandial hypoglycemia. Secondary meal outcomes (Figure 1B) included starting glucose, peak glucose, meal glucose rise (peak minus start), rise velocity (rise divided by time from start to peak), meal glucose fall (absolute value of trough minus peak) and fall velocity (fall divided by time from peak to trough). Area under curve (AUC) was calculated from meal start to trough using the trapezoidal rule (Python sklearn.metrics.auc). All continuous meal outcomes were log-transformed due to skewness. Meal hypoglycemia was also assessed as a dichotomous outcome, defined as meal trough glucose <70 mg/dL. Meal outcomes were analyzed for all meals and then repeated analyzing a subset restricted to the first meal per day, to reduce meal-to-meal heterogeneity.
Summative CGM outcomes were mean glucose, glucose management indicator (GMI=3.31+[0.02392 × mean glucose]), standard deviation and percent time in the following ranges: 70–180 mg/dL (time in range), 70–140 mg/dL (time in tight range), >180 mg/dL, >250 mg/dL, <70 mg/dL and <54 mg/dL. Summative CGM outcomes were computed for the matched cohort using their raw, 30-day CGM data without interpolation or smoothing (as might be available in a clinical setting), via R package iGlu (4.0.1). These CGM metrics were analyzed for the full 24 h per day, then repeated limited to typical waking hours (6–12AM [26]), a proxy for the mealtime period.
Meal annotation algorithm
Broadly, the meal annotation algorithm takes smoothed CGM data; identifies meals by searching for a trio of meal peak, trough, then preceding starting glucose; and extracts key CGM interstitial glucose (herein glucose) values. We extracted the CGM glucose values from the 30-day windows prior to each index date from the BCH Dexcom Clarity dataset (downloaded November 11, 2023) using R (version 3.6.2) on the BCH Enkefalos-v2 (E2) high-performance computing cluster (Linux operating system). Meal annotation was conducted using Python (version 3.9.13) with packages scipy (1.9.1), numpy (1.21.5), pandas (1.4.4) and sklearn (1.0.2).
First, for more reliable meal detection while minimizing non-physiologic fluctuations, missing glucose data were imputed using linear interpolation and high-frequency fluctuations >0.0005 Hz [27] were smoothed using a low pass filter. Then, peaks were identified during typical waking hours (6–12 AM) using scipy.signal.find_peaks to search the glucose data for features matching the following parameters: peak height ≥100 mg/dL, ≥2 h between peaks, rise ≥50 mg/dL above baseline and with elevated glucose ≥30 min duration. Similarly, troughs were identified as follows: trough glucose ≥15 min to ≤4 h after peak, fall ≥15 mg/dL below baseline for ≥15 min duration. Troughs were restricted to 6–3 AM to allow for a trough following a late-night meal while filtering out overnight fasting lows. The lowest trough glucose following each peak was selected. Last, the start of each meal was defined as the nearest glucose inflection from downtrending to uptrending glucose during waking hours ≤4 h before meal peak and with ≥50 mg/dL glucose increase from meal start to peak.
Data sufficiency for inclusion
To be eligible for matching, individuals were required to have at least 14 days of CGM data with ≥0.5 qualifying meals per day on average. Meals were disqualified if glucose values (prior to imputation) were missing ≤15 min before or after meal start, peak or trough; or if, from meal start to trough, more than 30 % of expected glucose values were missing or the glucose rate of change was >6 mg/dL/min [28].
Statistical analyses
Patient characteristics were compared between groups using Wilcoxon rank-sum or Fisher’s exact tests. Linear mixed models were used to compare meal outcomes between CD groups in the matched cohort with a fixed effect for matched strata (adjusting for confounding from covariates) and a random effect for subject (accounting for correlation between repeated measures from individuals). For the log-transformed outcomes, effect estimates represent the percent change in the CD+ relative to the CD− group, calculated by exponentiating the coefficient (beta), subtracting 1 and multiplying by 100. Mixed effects logistic regression was used to compare meal hypoglycemia between CD groups, using the same fixed and random effects. Rank-based van Elteren tests were used to compare summative CGM metrics between the CD groups, adjusting for matched strata. All prandial and summative CGM outcome calculations and statistical analyses were conducted using R (version 4.3.2) using two-sided 0.05 level tests.
Data availability and reporting guidelines
The datasets and code generated and/or analyzed in this study are available from the corresponding author upon reasonable request. We used the STROBE reporting guideline [29] to draft this manuscript, and the STROBE reporting checklist [30] when editing.
Results
Study cohort characteristics
During the study period, 1,531 individuals were diagnosed with T1D and 921 had recorded CD serologies <1 year of diabetes diagnosis. Of these, 850 were age 2–21 years with recently recorded BMI and HbA1c required for matching. Three hundred individuals also had CGM data available in the 30-day exposure window prior to CD serologies, and 288 met data sufficiency criteria, leaving 16 CD+ and 272 CD− individuals for matching.
The matched cohort comprised 16 CD+ and 60 CD− individuals: 13 CD+ matched exactly with four CD− individuals, two matched with three CD− individuals and one matched with two CD− individuals. The combined matched cohort was 70 % female and 75 % non-Hispanic White with median age 11.1 years (interquartile range 8.9–13.3), BMI z-score 0.23 (−0.15 to 0.61), diabetes duration 3.2 months (1.5–5.0) and HbA1c 7.3 % (6.3–8.4). There were 2,067 days of CGM data analyzed (median 30 days/subject [25.8–30.0]) and 3,659 meals analyzed (median 48.5 meals/subject [34.5–62.5]). There were no statistically significant differences with respect to these characteristics between CD+ and CD− groups (Table 1).
Matched cohort characteristics by celiac disease exposure status.
CD− group | CD+ group | |
---|---|---|
n=60 | n=16 | |
Sexa, no., % female | 42 (70) | 11 (69) |
Agea, years | 11.6 (9.1–14.1) | 10.6 (9.4–11.9) |
BMIa (z-score) | 0.23 (−0.12–0.58) | 0.36 (−0.07–0.78) |
Diabetes durationa, months | 3.1 (1.5–4.8) | 4.3 (2.4–6.3) |
Hemoglobin A1ca | ||
% | 7.3 (6.3–8.3) | 7.4 (5.8–8.9) |
mmol/mol | 56 (45–67) | 57 (40–74) |
Race/ethnicity, no., % | ||
Asian | 3 (5) | 0 |
Black | 3 (5) | 1 (6) |
Hispanic | 3 (5) | 0 |
White | 45 (75) | 12 (75) |
Unknownb | 6 (10) | 3 (19) |
Days of CGM data | ||
Total per group | 1,628 | 439 |
Days per subject | 30 (25.8–30.0) | 30 (27.3–30.0) |
Percent expected readings per subject | 95 (91–99) | 97 (94–99) |
Meals analyzed | ||
Total per group | 2,833 | 826 |
Meals per subject | 47 (33–60) | 57 (44–69) |
-
Data are presented as median (interquartile range) unless otherwise indicated. There were no statistically significant differences between groups. CD−, no celiac disease; CD+, undiagnosed celiac disease; CGM, continuous glucose monitoring. aCD+ matched to CD−on, dichotomized sex, age; BMI, diabetes duration and hemoglobin A1c. bUnknown designates that the field was completed as “unknown”, “other”, or “declined to answer”.
Prandial glucose dynamics
Our primary outcome, meal trough glucose, broadly operationalized the hypothesis that undiagnosed CD is associated with post-prandial hypoglycemia, evaluating for any change in trough glucose even if not meeting criteria for hypoglycemia. Using a linear mixed model, there was no significant difference in meal trough glucose between the as-yet undiagnosed CD+ group and the unexposed CD−group (−8.2 % effect estimate, 95 % CI, −20.1–5.5 %, p=0.23; Table 2). Undiagnosed CD was also not associated with meal hypoglycemia, defined as meal trough glucose <70 mg/dL (17.1 % CD+ vs. 13.9 % CD−meals, odds ratio 1.32, 95 % CI, 0.72 to 2.45, p=0.36).
Prandial glycemic outcomes by celiac disease exposure status.
CD− group | CD+ group | Effect estimate | p-Value | |
---|---|---|---|---|
n=60 | n=16 | |||
All meals | ||||
|
||||
Start, mg/dL | 114 (96–137) | 104 (94–130) | −5.8 % (−17.3–7.2 %) | 0.37 |
Peak, mg/dL | 213 (185–266) | 186 (173–241) | −7.9 % (−16.6–1.8 %) | 0.11 |
Trough, mg/dL | 103 (85–134) | 93 (83–117) | −8.2 % (−20.1–5.5 %) | 0.23 |
Rise, mg/dL | 90 (82–100) | 80 (75–94) | −8.9 % (−14.9–−2.5 %) | 0.009 |
Fall, mg/dL | 100 (91–111) | 91 (85–101) | −6.7 % (−13.3–0.5 %) | 0.07 |
Rise velocity, mg/dL/min | 1.24 (1.08–1.51) | 1.21 (1.08–1.40) | −6.4 % (−14.4–2.2 %) | 0.15 |
Fall velocity, mg/dL/min | 0.79 (0.69–0.95) | 0.84 (0.65–0.86) | −5.9 % (−13.6–2.5 %) | 0.17 |
AUC, mg/dL/h | 599 (490–684) | 531 (436–646) | −8.8 % (−20.7–5.0 %) | 0.20 |
|
||||
First meal per subject per day | ||||
|
||||
Start, mg/dL | 112 (96–136) | 104 (96–132) | −3.7 % (−15.1–9.2 %) | 0.56 |
Peak, mg/dL | 214 (191–277) | 196 (179–233) | −7.3 % (−16.2–2.4 %) | 0.14 |
Trough, mg/dL | 102 (81–131) | 96 (83–119) | −5.3 % (−18.0–9.3 %) | 0.46 |
Rise, mg/dL | 105 (94–121) | 96 (89–108) | −10.5 % (−17.8–−2.4 %) | 0.01 |
Fall, mg/dL | 91 (81–109) | 83 (72–98) | −9.3 % (−16.–−1.5 %) | 0.02 |
Rise velocity, mg/dL/min | 1.35 (1.09–1.59) | 1.31 (1.06–1.63) | −3.1 % (−12.3–7.0 %) | 0.54 |
Fall velocity, mg/dL/min | 0.79 (0.68–0.95) | 0.76 (0.69–0.88) | −7.7 % (−15.3–0.7 %) | 0.08 |
AUC, mg/dL/h | 605 (513–860) | 516 (454–646) | −9.6 % (−22.6–5.5 %) | 0.20 |
-
Meal outcomes are presented as the group median (interquartile range) of the median outcome per individual. Outcomes were compared using linear mixed models adjusting for matched strata and accounting for correlation between repeated measures from individuals. Meal glucose rise was calculated as peak minus start glucose and rise velocity was calculated as rise divided by time from start to peak. Meal glucose fall was calculated as the absolute value of trough minus peak glucose and fall velocity was calculated as fall divided by time from peak to trough. All meal outcomes were log-transformed and effect estimates are presented as percent changes (95 % confidence interval). CD−, no celiac disease; CD+, undiagnosed celiac disease; AUC, area under curve.
We then assessed for other changes in prandial glucose dynamics in the setting of T1D and undiagnosed CD. The meal glucose rise (increase from start to peak) was significantly lower among CD+ compared to CD− (−8.9 % effect estimate, 95 % CI, −14.9–−2.5 %, p=0.009). The meal glucose fall (decrease from peak to trough) was also lower in the CD+ group, though not reaching statistical significance (−6.7 % effect estimate, 95 % CI, −13.3–0.5 %, p=0.07, Figure 2A). Similarly, other related meal outcomes including peak glucose, rise velocity, fall velocity and AUC had negative effect estimates but did not reach statistical significance (Table 2).

Blunted meal glucose excursions in youth with undiagnosed celiac disease and type 1 diabetes. Data from the CD−group are shown in orange and data from the CD+ group are shown in blue. (A–B) comparison of distribution of meal glucose rise, fall and trough for (A) all meals and (B) a subset consisting of the first meal per day (first meals). Rise was calculated as meal glucose peak minus start and fall was calculated as the absolute value of meal glucose trough minus peak. Boxes represent the interquartile range (IQR, 25th to 75th percentile). Horizontal lines inside the boxes denote median values, whiskers outside the boxes extend to 1.5 × IQR and dots denote outliers outside 1.5 × IQR. (C–D) mean of mean meal glucose per individual (solid circles) and 95 % confidence intervals (shaded regions) for (C) all meals and (D) the subset of first meals. Timepoint-wise mean glucose was calculated at each 5-min increment following meal start, first by individual, then across the CD groups. Meals were of variable durations and the number of individuals with data at each time increment is represented by circle size. To generate representative illustrations of meal glucose patterns, the longest 5 % of meals per individual were excluded, then the longest 5 % of all remaining meals were excluded. CGM, continuous glucose monitoring; CD−, no celiac disease; CD+, undiagnosed celiac disease; *p<0.05, **p<0.01. Created in BioRender. Ruiz, J. (2025) https://BioRender.com/ulrxr00.
We then repeated the analysis with CGM meal data limited to the first meal of each day to reduce the impact of heterogeneity from inter-prandial glycemia and potential diurnal variation in insulin sensitivity and/or meal glycemic index. Within this subset of first meals, undiagnosed CD was again associated with a significantly reduced meal glucose rise (−10.5 % effect estimate, 95 % CI, −17.8–−2.4 %, p=0.01) and a significantly reduced meal glucose fall (−9.3 % effect estimate, 95 % CI, −16.5–−1.5 %, p=0.02, Figure 2B). The fall velocity was also slower in the CD+ group, though not reaching statistical significance (−7.7 % effect estimate, 95 % CI, −15.3–0.7 %, p=0.08). There were no significant differences between groups in trough glucose or the other secondary outcomes, though effect estimates were all negative (Table 2). Figure 2 illustrates representative CGM meal glucose data for all meals (Figure 2C) and the subset of first meals (Figure 2D).
Summative glucose metrics
Last, we analyzed differences in 30-day summative CGM metrics (that might be available at a clinical visit) in relation to celiac status. Among individuals in the cohort, there was a median of 95.3 % (91.9–98.7 %) of expected CGM values available, with only one individual with <70 % of expected CGM values (56.6 %). The summative CGM metrics, including time below 70 mg/dL and time below 54 mg/dL, did not significantly differ between groups when calculated over the full 24 h per day or when limited to waking hours (Table 3).
Summative continuous glucose monitoring metrics by celiac disease exposure status.
CD− group | CD+ group | p-Value | |
---|---|---|---|
n=60 | n=16 | ||
All data | |||
|
|||
GMI, % | 6.9 (6.5–7.7) | 6.6 (6.3–7.5) | 0.27 |
Mean, mg/dL | 152 (132–183) | 139 (126–174) | 0.27 |
SD, mg/dL | 48 (41–62) | 44 (35–66) | 0.32 |
Time in range, 70–180 mg/dL, % | 76 (53–85) | 81 (60–89) | 0.25 |
Time in tight range, 70–140 mg/dL, % | 48 (28–64) | 57 (33–68) | 0.27 |
Time above 180 mg/dL, % | 24 (14–46) | 16 (9–40) | 0.23 |
Time above 250 mg/dL, % | 4 (2–16) | 2 (0–15) | 0.13 |
Time below 70 mg/dL, % | 0.7 (0.3–1.6) | 0.9 (0.3–2.0) | 0.60 |
Time below 54 mg/dL, % | 0.07 (0.02–0.19) | 0.06 (0.04–0.14) | 0.95 |
|
|||
Waking hours (6 AM to 12 AM) | |||
|
|||
GMI, % | 7.0 (6.5–7.9) | 6.7 (6.2–7.6) | 0.17 |
Mean, mg/dL | 155 (134–192) | 141 (122–178) | 0.17 |
SD, mg/dL | 50 (42–63) | 45 (35–66) | 0.25 |
Time in range, 70–180 mg/dL, % | 72 (48–85) | 81 (56–90) | 0.17 |
Time in tight range, 70–140 mg/dL, % | 45 (25–61) | 55 (31–71) | 0.12 |
Time above 180 mg/dL, % | 27 (14–51) | 17 (7–44) | 0.13 |
Time above 250 mg/dL, % | 5 (1–19) | 2 (0–14) | 0.10 |
Time below 70 mg/dL, % | 0.8 (0.3–1.6) | 1.0 (0.4–2.3) | 0.44 |
Time below 54 mg/dL, % | 0.08 (0.01–0.21) | 0.07 (0.05–0.18) | 0.73 |
-
Data are presented as median (interquartile range). Metrics were compared between groups using van Elteren tests adjusting for matched strata. CGM, continuous glucose monitoring; CD−, no celiac disease; CD+, undiagnosed celiac disease; GMI, glucose management index; SD, standard deviation.
Discussion
We demonstrate an attenuated meal glucose rise and fall in children with T1D immediately prior to CD diagnosis compared to matched individuals without CD, leveraging analyses of prandial CGM dynamics identified using a novel meal annotation algorithm. Importantly, our study showed there were no significant differences in prandial trough glucose, meal hypoglycemia or time hypoglycemic in this cohort of CGM users, despite the frequent citation of increased hypoglycemia as a clinical indicator of possible undiagnosed CD.
This is the first study to our knowledge that utilized CGM to assess the association between CD and glycemia just prior to CD diagnosis in a T1D cohort of CGM users, as prior CGM studies have focused on the impact of gluten-free diets after CD diagnosis [31], [32], [33]. Further, this study is the first within the dual T1D and CD population to apply an informatics methodology to retrospectively identify probable meal glucose excursions without meal diaries, in contrast to prior analyses requiring documentation of meal events [33]. While the algorithm was not tested on a dataset with verified meal events, it was developed using physiology-based parameters and systematically applied across the cohort. Our computational approach could aid researchers in automating assessment of prandial CGM events (e.g., meals) and dynamics (e.g., meal rise) within pre-existing CGM data without placing an additional burden of event logging on patients.
CD enteropathy causes damaged villi and dysmotility (delayed gastrointestinal transit [34]), both of which can drive prandial insulin-glucose mismatch via incomplete and delayed carbohydrate absorption. Thus, our findings of blunted prandial glucose rise, fall and slower fall velocity are concordant with the underlying pathophysiology of untreated CD. This was accentuated when restricting analyses to the first meal of each day (often containing more carbohydrates) and so CD malabsorption may be modulated by meal carbohydrate and/or gluten content. Despite fewer observations, the first-meal analyses strengthened several associations, likely by reducing heterogeneity from meal overlap, meal composition and diurnal changes in insulin sensitivity.
Complementary methods to identify patients at highest risk of CD are needed, as current guidelines lack quantitative glycemic measures of subclinical changes that indicate a need for CD testing. Pediatric guidelines recommend infrequent CD screening every 2–5 years [4], with less clear guidance beyond the first 5 years after T1D diagnosis [5], which can result in large gaps between screening. Our findings of attenuated prandial glucose rise and fall are novel, dynamic CGM biomarkers that, in future studies, could be refined, expanded upon and incorporated into a predictive model of CD in T1D. A predictive model can integrate multiple significant CGM and clinical features to help risk-stratify patients and guide CD evaluation, and could be integrated into CGM platforms, potentially enabling real-time celiac risk assessment without additional clinical burden.
Post-prandial hypoglycemia has been proposed as an identifiable glycemic feature to prompt testing for CD in T1D [4], 5]. However, in this cohort of CGM users, we observed no significant difference in post-prandial trough glucose, meal hypoglycemia or any summative CGM metrics standardly reviewed in a clinical encounter. Our results complement findings from prior studies of treated vs. untreated CD in T1D, in which CGM analyses revealed no difference in hypoglycemic episodes or other CGM metrics [31], 32]. There are several clinical factors that might explain why untreated CD was not associated with hypoglycemia in this cohort. Importantly, our cohort was exclusively comprised of individuals using CGM, which provides anticipatory alerts prompting intervention before hypoglycemia occurs. Providers may have lowered insulin doses for CD+ individuals experiencing hypoglycemia, reducing insulin-glucose mismatch. Further, this study assessed children during the first year following diabetes diagnosis (selected as a time of systematic CD screening in our practice), when some endogenous insulin and glucagon production remains and can mitigate hypoglycemia. Lastly, the degree of malabsorption and resulting glycemic sequelae in CD is variable and not reliably correlated with serologies. Nonetheless, these clinical factors and our findings argue against the primacy of unexplained hypoglycemia as the distinguishing glycemic feature of CD among children with T1D using CGM.
This retrospective study was strengthened by the matched cohort design, which adjusted for important physiologic covariates, including the increased risk of hypoglycemia in new-onset T1D as children enter remission and require less exogenous insulin. CGM data missingness was counterbalanced by numerous rules for data sufficiency. Additionally, CGM data assessment before CD serologies mitigated confounding from patient knowledge and potential gluten-free diet. Data were not uniformly available to adjust for additional effect modifiers, including insulin dosing, meal composition and endogenous β-cell function (e.g. c-peptide). HbA1c was not uniformly measured at the index date, but the distribution of HbA1c and GMI were similar among the cohort, indicating that HbA1c measurements used were a reasonable approximation for glycemia during the exposure window. The cohort had a small sample size with limited racial/ethnic diversity and was restricted to children at a single academic medical center using CGM during the first year of diabetes, thus limiting generalizability beyond this context.
Conclusions
In conclusion, this study leveraged a computational meal annotation algorithm to demonstrate blunting of meal glycemic excursions prior to CD diagnosis vs. no CD diagnosis in a matched cohort of children with new-onset T1D using CGM. Hypoglycemia did not differ between groups but is often cited as a glycemic feature of emerging CD in T1D. Thus, this work lays the foundation for a new risk-assessment paradigm leveraging prandial glycemic biomarkers beyond hypoglycemia to identify increased CD risk among CGM users. Findings from this and future work in broader T1D populations can inform a CGM-based model for real-time prediction of CD to help drive earlier diagnosis and mitigate the consequences of CD in T1D.
Funding source: Pediatric Scientist Development Program
Funding source: Cystic Fibrosis Foundation
Funding source: National Science Foundation
Award Identifier / Grant number: 2141064
Funding source: National Institute of Diabetes and Digestive and Kidney Diseases
Award Identifier / Grant number: T32DK007699, K23DK119584, K23DK120899
Acknowledgments
The authors thank Sarah Clemons, BSN (BCH Clinical Research Operations Center), Elise Tremblay, MD, MPH (BCH Division of Endocrinology) and the BCH Celiac Disease Research Group for their contributions to data collection, and Josué López, PhD, for advice regarding figure design. The authors acknowledge Boston Children’s Hospital’s High-Performance Computing Resources BCH HPC Clusters Enkefalos 2 (E2) made available for conducting the research reported in this publication. Figures were created in BioRender, Ruiz, J. (2025), https://BioRender.com/2x4rz0m (Figure 1), https://BioRender.com/ulrxr00 (Figure 2).
-
Research ethics: This study was conducted in accordance with the Declaration of Helsinki. This study protocol was reviewed and received Ethical Approval from the Boston Children’s Hospital Institutional Review Board, approval number IRB-P00032591 on July 12, 2019.
-
Informed consent: The need for written informed consent was waived for this retrospective study by the Institutional Review Board.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission. J.L.R. was involved in the conception, design and conduct of the study, data acquisition, and the statistical analysis and interpretation of the results. L.A.A. and D.W. were involved in the study design and conduct of the study, and the statistical analysis and interpretation of the results. C.M.A., J.A.S. and M.S.D.A. were involved in the study conception, design and conduct and interpretation of the results. A.S.B. was involved in the study conduct, data acquisition and analysis. E.H. was involved in the study conduct and data analysis. J.L.R. wrote the first draft of the manuscript, and all authors edited, reviewed and approved the final version of the manuscript.
-
Use of Large Language Models, AI and Machine Learning Tools: The authors acknowledge the use of Claude (Anthropic, Claude Sonnet 4) for language enhancement.
-
Conflict of interest: The author team reports in-kind support of CGM devices from DexCom Inc. (San Diego, CA, USA), for a different study of another disease. All patients in the current manuscript used their personal, prescribed Dexcom devices, and no devices were donated by Dexcom. There is no relationship between the current manuscript and the ongoing, Dexcom-supported study.
-
Research funding: This work was supported by the Pediatric Scientist Development Program with funding from the Cystic Fibrosis Foundation (J.L.R.). Time on this work was supported by the National Institutes of Health [grant numbers T32DK007699 (J.L.R.), K23DK119584 (J.A.S.), K23DK120899 (C.M.A)]; and the National Science Foundation [grant number 2141064 (E.H.)]. The funders had no role in the design, data collection, data analysis, and reporting of this study.
-
Data availability: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
-
Software availability: The software generated during the current study are available from the corresponding author on reasonable request.
References
1. Leonard, MM, Cureton, PA, Fasano, A. Managing coeliac disease in patients with diabetes. Diabetes Obe Metab 2015;17:3–8. https://doi.org/10.1111/dom.12310.Search in Google Scholar PubMed
2. Craig, ME, Prinz, N, Boyle, CT, Campbell, FM, Jones, TW, Hofer, SE, et al.. Prevalence of celiac disease in 52,721 youth with type 1 diabetes: international comparison across three continents. Diabetes Care 2017;40:1034–40. https://doi.org/10.2337/dc16-2508.Search in Google Scholar PubMed PubMed Central
3. Smyth, DJ, Plagnol, V, Walker, NM, Cooper, JD, Downes, K, Yang, JHM, et al.. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008;359:2767–77. https://doi.org/10.1056/nejmoa0807917.Search in Google Scholar PubMed PubMed Central
4. Fröhlich-Reiterer, E, Elbarbary, NS, Simmons, K, Buckingham, B, Humayun, KN, Johannsen, J, et al.. ISPAD clinical practice consensus guidelines 2022: other complications and associated conditions in children and adolescents with type 1 diabetes. Pediatr Diabetes 2022;23:1451–67. https://doi.org/10.1111/pedi.13445.Search in Google Scholar PubMed
5. McCoy, RG, Aleppo, G, Balapattabi, K, Beverly, EA, Briggs Early, K. 14. children and adolescents standards of care in diabetes-2025. Diabetes Care 2025;48:S283–305. https://doi.org/10.2337/dc25-s014.Search in Google Scholar
6. Kakleas, K, Soldatou, A, Karachaliou, F, Karavanaki, K. Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus (T1DM). Autoimmun Rev 2015;14:781–97. https://doi.org/10.1016/j.autrev.2015.05.002.Search in Google Scholar PubMed
7. Camarca, ME, Mozzillo, E, Nugnes, R, Zito, E, Falco, M, Fattorusso, V, et al.. Celiac disease in type 1 diabetes mellitus. Ital J Pediatr 2012;38:10. https://doi.org/10.1186/1824-7288-38-10.Search in Google Scholar PubMed PubMed Central
8. Taler, I, Phillip, M, Lebenthal, Y, de Vries, L, Shamir, R, Shalitin, S. Growth and metabolic control in patients with type 1 diabetes and celiac disease: a longitudinal observational case-control study. Pediatr Diabetes 2012;13:597–606. https://doi.org/10.1111/j.1399-5448.2012.00878.x.Search in Google Scholar PubMed
9. Kaur, N, Bhadada, SK, Minz, RW, Dayal, D, Kochhar, R. Interplay between type 1 diabetes mellitus and celiac disease: implications in treatment. Dig Dis 2018;36:399–408. https://doi.org/10.1159/000488670.Search in Google Scholar PubMed
10. Stahl, MG, Geno Rasmussen, C, Dong, F, Waugh, K, Norris, JM, Baxter, J, et al.. Mass screening for celiac disease: the autoimmunity screening for kids study. Am J Gastroenterol 2021;116:180–7. https://doi.org/10.14309/ajg.0000000000000751.Search in Google Scholar PubMed PubMed Central
11. Margoni, D, Chouliaras, G, Duscas, G, Voskaki, I, Voutsas, N, Papadopoulou, A, et al.. Bone health in children with celiac disease assessed by dual x-ray absorptiometry: effect of gluten-free diet and predictive value of serum biochemical indices. J Pediatr Gastroenterol Nutr 2012;54:680–4. https://doi.org/10.1097/mpg.0b013e31823f5fc5.Search in Google Scholar PubMed
12. Warncke, K, Liptay, S, Fröhlich-Reiterer, E, Scheuing, N, Schebek, M, Wolf, J, et al.. Vascular risk factors in children, adolescents, and young adults with type 1 diabetes complicated by celiac disease: results from the DPV initiative. Pediatr Diabetes 2016;17:191–8.10.1111/pedi.12261Search in Google Scholar PubMed
13. Salardi, S, Maltoni, G, Zucchini, S, Iafusco, D, Confetto, S, Zanfardino, A, et al.. Celiac disease negatively influences lipid profiles in young children with type 1 diabetes: effect of the gluten-free diet. Diabetes Care 2016;39:e119–20. https://doi.org/10.2337/dc16-0717.Search in Google Scholar PubMed
14. Mollazadegan, K, Kugelberg, M, Montgomery, SM, Sanders, DS, Ludvigsson, J, Ludvigsson, JF. A population-based study of the risk of diabetic retinopathy in patients with type 1 diabetes and celiac disease. Diabetes Care 2013;36:316–21. https://doi.org/10.2337/dc12-0766.Search in Google Scholar PubMed PubMed Central
15. Rohrer, TR, Wolf, J, Liptay, S, Zimmer, KP, Fröhlich-Reiterer, E, Scheuing, N, et al.. Microvascular complications in childhood-onset type 1 diabetes and celiac disease: a multicenter longitudinal analysis of 56,514 patients from the German-Austrian DPV database. Diabetes Care 2015;38:801–7. https://doi.org/10.2337/dc14-0683.Search in Google Scholar PubMed
16. Biempica, L, Toccalino, H, O’Donnell, JC. Cytochemical and ultrastructural studies of the intestinal mucosa of children with celiac disease. Am J Pathol 1968;52:795–823.Search in Google Scholar
17. Mohn, A, Cerruto, M, Iafusco, D, Prisco, F, Tumini, S, Stoppoloni, O, et al.. Celiac disease in children and adolescents with type I diabetes: importance of hypoglycemia. J Pediatr Gastroenterol Nutr 2001;32:37–40. https://doi.org/10.1002/j.1536-4801.2001.tb07203.x.Search in Google Scholar
18. Iafusco, D, Rea, F, Prisco, F. Hypoglycemia and reduction of the insulin requirement as a sign of celiac disease in children with IDDM. Diabetes Care 1998;21:1379–81. https://doi.org/10.2337/diacare.21.8.1379.Search in Google Scholar
19. Sun, S, Puttha, R, Ghezaiel, S, Skae, M, Cooper, C, Amin, R. The effect of biopsy-positive silent coeliac disease and treatment with a gluten-free diet on growth and glycaemic control in children with type 1 diabetes. Diabet Med 2009;26:1250–4. https://doi.org/10.1111/j.1464-5491.2009.02859.x.Search in Google Scholar PubMed
20. Goh, VL, Estrada, DE, Lerer, T, Balarezo, F, Sylvester, FA. Effect of gluten-free diet on growth and glycemic control in children with type 1 diabetes and asymptomatic celiac disease. J Pediatr Endocrinol Metab 2010;23:1169–73. https://doi.org/10.1515/jpem.2010.183.Search in Google Scholar PubMed
21. Simmons, JH, Klingensmith, GJ, McFann, K, Rewers, M, Ide, LM, Taki, I, et al.. Celiac autoimmunity in children with type 1 diabetes: a two-year follow-up. J Pediatr 2011;158:276–81.e1. https://doi.org/10.1016/j.jpeds.2010.07.025.Search in Google Scholar PubMed PubMed Central
22. Barua, S, Sabharwal, A, Glantz, N, Conneely, C, Larez, A, Bevier, W, et al.. The northeast glucose drift: stratification of post-breakfast dysglycemia among predominantly hispanic/latino adults at-risk or with type 2 diabetes. eClinicalMedicine 2022;43:101241. https://doi.org/10.1016/j.eclinm.2021.101241.Search in Google Scholar PubMed PubMed Central
23. Husby, S, Koletzko, S, Korponay-Szabó, I, Kurppa, K, Mearin, ML, Ribes-Koninckx, C, et al.. European society paediatric gastroenterology, hepatology and nutrition guidelines for diagnosing coeliac disease 2020. J Pediatr Gastroenterol Nutr 2020;70:141–56. https://doi.org/10.1097/mpg.0000000000002497.Search in Google Scholar PubMed
24. Herman-Giddens, ME, Steffes, J, Harris, D, Slora, E, Hussey, M, Dowshen, SA, et al.. Secondary sexual characteristics in boys: data from the pediatric research in office settings network. Pediatrics 2012;130:e1058–68. https://doi.org/10.1542/peds.2011-3291.Search in Google Scholar PubMed
25. Rosenfield, RL, Lipton, RB, Drum, ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 2009;123:84–8. https://doi.org/10.1542/peds.2008-0146.Search in Google Scholar PubMed
26. Danne, T, Nimri, R, Battelino, T, Bergenstal, RM, Close, KL, DeVries, JH, et al.. International consensus on use of continuous glucose monitoring. Diabetes Care 2017;40:1631–40. https://doi.org/10.2337/dc17-1600.Search in Google Scholar PubMed PubMed Central
27. Breton, MD, Shields, DP, Kovatchev, BP. Optimum subcutaneous glucose sampling and fourier analysis of continuous glucose monitors. J Diabetes Sci Technol 2008;2:495–500. https://doi.org/10.1177/193229680800200322.Search in Google Scholar PubMed PubMed Central
28. Jungheim, K, Kapitza, C, Djurhuus, CB, Wientjes, KJ, Koschinsky, T. How rapid does blood glucose concentration change in daily-life of patients with type 1 diabetes? In: Diabetologia. New York, NY 10010 USA: Springer-Verlag 175 Fifth AvE; 2002:A276 p.Search in Google Scholar
29. von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573–7. https://doi.org/10.7326/0003-4819-147-8-200710160-00010.Search in Google Scholar PubMed
30. von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP. The EQUATOR network reporting guideline platform [Internet]. UK Equator Cent 2025. [Internet] [cited 2025 Mar 5]; Available from https://resources.equator-network.org/guidelines/strobe/strobe-checklist.docx.Search in Google Scholar
31. Kaur, P, Agarwala, A, Makharia, G, Bhatnagar, S, Tandon, N. Effect of gluten-free diet on metabolic control and anthropometric parameters in type 1 diabetes with subclinical celiac disease: a randomized controlled trial. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 2020;26:660–7. https://doi.org/10.4158/ep-2019-0479.Search in Google Scholar
32. Mahmud, FH, Clarke, ABM, Joachim, KC, Assor, E, McDonald, C, Saibil, F, et al.. Screening and treatment outcomes in adults and children with type 1 diabetes and asymptomatic celiac disease: the CD−DIET study. Diabetes Care 2020;43:1553–6. https://doi.org/10.2337/dc19-1944.Search in Google Scholar PubMed
33. Pham-Short, A, Donaghue, KC, Ambler, G, Garnett, S, Craig, ME. Greater postprandial glucose excursions and inadequate nutrient intake in youth with type 1 diabetes and celiac disease. Sci Rep 2017;7:45286. https://doi.org/10.1038/srep45286.Search in Google Scholar PubMed PubMed Central
34. Usai-Satta, P, Oppia, F, Lai, M, Cabras, F. Motility disorders in celiac disease and non-celiac gluten sensitivity: the impact of a gluten-free diet. Nutrients 2018;10. https://doi.org/10.3390/nu10111705.Search in Google Scholar PubMed PubMed Central
© 2025 the author(s), published by De Gruyter, Berlin/Boston
This work is licensed under the Creative Commons Attribution 4.0 International License.